Alpha 2.0
Login Register
» Authors » George Hickman

George Hickman

Explore the profile of George Hickman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 642
Followers 0
Related Specialties
General Medicine
Public Health
Biomedical Engineering
Top 10 Co-Authors
Brian Mackenna
Ben Goldacre
Amir Mehrkar
David Evans
Simon Davy
John Parry
Frank Hester
Peter Inglesby
Sam Harper
Jonathan Cockburn
Published In
Wellcome Open Res
Br J Gen Pract
BMJ
BMJ Med
Br J Clin Pharmacol
Affiliations
Soon will be listed here.
Recent Articles
11.
Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform
Nab L, Parker E, Andrews C, Hulme W, Fisher L, Morley J, et al.
Lancet Public Health . 2023 Apr; 8(5):e364-e377. PMID: 37120260
Background: COVID-19 has been shown to differently affect various demographic and clinical population subgroups. We aimed to describe trends in absolute and relative COVID-19-related mortality risks across clinical and demographic...
12.
OpenSAFELY NHS Service Restoration Observatory 2: changes in primary care clinical activity in England during the COVID-19 pandemic
Curtis H, Mackenna B, Wiedemann M, Fisher L, Croker R, Morton C, et al.
Br J Gen Pract . 2023 Apr; 73(730):e318-e331. PMID: 37068964
Background: The COVID-19 pandemic has disrupted healthcare activity across a broad range of clinical services. The NHS stopped non-urgent work in March 2020, later recommending services be restored to near-normal...
13.
Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
Green A, Curtis H, Higgins R, Nab L, Mahalingasivam V, Smith R, et al.
BMJ Med . 2023 Mar; 2(1):e000276. PMID: 36936265
Objective: To ascertain patient eligibility status and describe coverage of antiviral drugs and neutralising monoclonal antibodies (nMAB) as treatment for covid-19 in community settings in England. Design: Retrospective, descriptive cohort...
14.
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform
Zheng B, Green A, Tazare J, Curtis H, Fisher L, Nab L, et al.
BMJ . 2022 Nov; 379:e071932. PMID: 36384890
Objective: To compare the effectiveness of sotrovimab (a neutralising monoclonal antibody) with molnupiravir (an antiviral) in preventing severe outcomes of covid-19 in adult patients infected with SARS-CoV-2 in the community...
15.
Recording of 'COVID-19 vaccine declined': a cohort study on 57.9 million National Health Service patients' records in situ using OpenSAFELY, England, 8 December 2020 to 25 May 2021
Curtis H, Inglesby P, Mackenna B, Croker R, Hulme W, Rentsch C, et al.
Euro Surveill . 2022 Aug; 27(33). PMID: 35983770
BackgroundPriority patients in England were offered COVID-19 vaccination by mid-April 2021. Codes in clinical record systems can denote the vaccine being declined.AimWe describe records of COVID-19 vaccines being declined, according...
16.
OpenSAFELY: Representativeness of electronic health record platform OpenSAFELY-TPP data compared to the population of England
Andrews C, Schultze A, Curtis H, Hulme W, Tazare J, Evans S, et al.
Wellcome Open Res . 2022 Aug; 7:191. PMID: 35966958
Since its inception in March 2020, data from the OpenSAFELY-TPP electronic health record platform has been used for more than 20 studies relating to the global COVID-19 emergency. OpenSAFELY-TPP data...
17.
Association between household composition and severe COVID-19 outcomes in older people by ethnicity: an observational cohort study using the OpenSAFELY platform
Wing K, Grint D, Mathur R, Gibbs H, Hickman G, Nightingale E, et al.
Int J Epidemiol . 2022 Aug; 51(6):1745-1760. PMID: 35962974
Background: Ethnic differences in the risk of severe COVID-19 may be linked to household composition. We quantified the association between household composition and risk of severe COVID-19 by ethnicity for...
18.
Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records
Horne E, Hulme W, Keogh R, Palmer T, Williamson E, Parker E, et al.
BMJ . 2022 Jul; 378:e071249. PMID: 35858698
Objective: To estimate waning of covid-19 vaccine effectiveness over six months after second dose. Design: Cohort study, approved by NHS England. Setting: Linked primary care, hospital, and covid-19 records within...
19.
Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY
Hulme W, Williamson E, Green A, Bhaskaran K, McDonald H, Rentsch C, et al.
BMJ . 2022 Jul; 378:e068946. PMID: 35858680
Objective: To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and the ChAdOx1 (Oxford-AstraZeneca) covid-19 vaccines against infection and covid-19 disease in health and social care workers. Design: Cohort study,...
20.
Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY
Green A, Curtis H, Hulme W, Williamson E, McDonald H, Bhaskaran K, et al.
BMC Med . 2022 Jul; 20(1):243. PMID: 35791013
Background: While the vaccines against COVID-19 are highly effective, COVID-19 vaccine breakthrough is possible despite being fully vaccinated. With SARS-CoV-2 variants still circulating, describing the characteristics of individuals who have...